top of page

Insights & Updates


Surviving the Phase II Cliff: Why So Many Promising Drugs Fail — and What We Can Do About It
For translational leaders, generating decision-quality data before risking millions in clinical trials is crucial. De-Risk Antibody Development with Tissue Insights Platform.
Featured
Search


Our new innovative tissue staining platform turns complexity into simplicity
Offspring Biosciences is pleased to announce our expanded technical capacity with the purchase and installment of a Roche/Ventana Discovery Ultra tissue staining platform which significantly enhances our ability to deliver highly reliable, informative and 7-Plex Multiplex IHC & ISH Services | Preclinical CRO | Offspring Bioefficient support to our customers The Discovery Ultra platform allows for parallel and fully individualized processing of up to 30 slide-mounted tissue
-
Sep 16, 20211 min read


Offspring assist AstraZeneca with diabetes project aimed to validate a potential novel biomarker
In a recently published study in Plos One, a research team led by Dr Sara Hansson at AstraZeneca presented data which demonstrate that secretagogin, an intracellular calcium-binding intracellular protein highly enriched in pancreatic islets, may serve as biomarker in the blood for beta cell dysfunction in individuals with type 2 diabetes Offspring supported this project by performing multiplexed immunofluorescence-based detection of secretagogin selectively within the insulin
-
Sep 16, 20212 min read


Offspring supports MedImmune in a study published in Diabetes
In a recently published study by a research team from MedImmune led by Dr. Arun Sharma, novel data was presented which shows that in vivo treatment with a combination of the neurotrophic factor neuturin (NRTN) and liraglutide in hyperglycemic ZDF rats synergistically improved glycemic control and enhanced metabolic parameters as compared to liraglutide alone, highlighting the potential of novel combinatorial approaches to prevent or reverse diabetes progression Offspring are
-
Sep 16, 20211 min read
bottom of page
